Olanzapine View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-09

AUTHORS

John T. Callaghan, Richard F. Bergstrom, Louis R. Ptak, Charles M. Beasley

ABSTRACT

Multicentre trials in patients with schizophrenia confirm that olanzapine is a novel antipsychotic agent with broad efficacy, eliciting a response in both the positive and negative symptoms of schizophrenia. Compared with traditional antipsychotic agents, olanzapine causes a lower incidence of extrapyramidal symptoms and minimal perturbation of prolactin levels. Generally, olanzapine is well tolerated. The pharmacokinetics of olanzapine are linear and dose-proportional within the approved dosage range. Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours. The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h. Smokers and men have a higher clearance of olanzapine than women and nonsmokers. After administering [14C]olanzapine, approximately 60% of the radioactivity was excreted in urine and 30% in faeces. Olanzapine is predominantly bound to albumin (90%) and alpha 1-acid glycoprotein (77%). Olanzapine is metabolised to its 10- and 4'-N-glucuronides, 4'-N-desmethylolanzapine [cytochrome P450 (CYP) 1A2] and olanzapine N-oxide (flavin mono-oxygenase 3). Metabolism to 2-hydroxymethylolanzapine via CYP2D6 is a minor pathway. The 10-N-glucuronide is the most abundant metabolite, but formation of 4'-N-desmethylolanzapine is correlated with the clearance of olanzapine. Olanzapine does not inhibit CYP isozymes. No clinically significant metabolic interactions were found between olanzapine and diazepam, alcohol (ethanol), imipramine, R/S-warfarin, aminophylline, biperiden, lithium or fluoxetine. Fluvoxamine, an inhibitor of CYP1A2, increases plasma concentrations of olanzapine; inducers of CYP1A2, including tobacco smoke and carbamazepine, decrease olanzapine concentrations. Orthostatic changes were observed when olanzapine and diazepam or alcohol were coadministered. Pharmacodynamic interactions occurred between olanzapine and alcohol, and olanzapine and imipramine, implying that patients should avoid operating hazardous equipment or driving an automobile while experiencing the short term effects of the combinations. Individual factors with the largest impact on olanzapine pharmacokinetics are gender and smoking status. The plasma clearance of olanzapine generally varies over a 4-fold range, but the variability in the clearance and concentration of olanzapine does not appear to be associated with the severity or duration of adverse effects or the degree of efficacy. Thus, dosage adjustments appear unnecessary for these individual factors. However, dosage modification should be considered for patients characterised by a combination of factors associated with decreased oxidative metabolism, for example, debilitated or elderly women who are nonsmokers. More... »

PAGES

177-193

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00003088-199937030-00001

DOI

http://dx.doi.org/10.2165/00003088-199937030-00001

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035394480

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10511917


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antipsychotic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzodiazepines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Comorbidity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Continental Population Groups", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pirenzepine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Indiana University \u2013 Purdue University Indianapolis", 
          "id": "https://www.grid.ac/institutes/grid.257413.6", 
          "name": [
            "Lilly Laboratory for Clinical Research, Indiana University Hospital and Outpatient Center, 550 North University Boulevard, 46202-5250, Indianapolis, Indiana, USA", 
            "Departments of Medicine and Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Callaghan", 
        "givenName": "John T.", 
        "id": "sg:person.01324115133.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324115133.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Indiana University \u2013 Purdue University Indianapolis", 
          "id": "https://www.grid.ac/institutes/grid.257413.6", 
          "name": [
            "Lilly Laboratory for Clinical Research, Indiana University Hospital and Outpatient Center, 550 North University Boulevard, 46202-5250, Indianapolis, Indiana, USA", 
            "Department of Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bergstrom", 
        "givenName": "Richard F.", 
        "id": "sg:person.0635603377.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635603377.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Lilly Laboratory for Clinical Research, Indiana University Hospital and Outpatient Center, 550 North University Boulevard, 46202-5250, Indianapolis, Indiana, USA", 
            "Trilogy Consulting Corporation, Waukeganm, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ptak", 
        "givenName": "Louis R.", 
        "id": "sg:person.01362603742.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362603742.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Laboratory for Clinical Research, Indiana University Hospital and Outpatient Center, 550 North University Boulevard, 46202-5250, Indianapolis, Indiana, USA", 
            "Eli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beasley", 
        "givenName": "Charles M.", 
        "id": "sg:person.01154671612.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154671612.61"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf02251294", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003233659", 
          "https://doi.org/10.1007/bf02251294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02251294", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003233659", 
          "https://doi.org/10.1007/bf02251294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/00498258409151404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010674459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/j.1875-9114.1998.tb03143.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011721679"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.1995.tb04422.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014592236"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.1982.tb02050.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016181259"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.1996.tb00180.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018563641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/j.1552-4604.1997.tb04272.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018789894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/0893-133x(94)00129-n", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020831678", 
          "https://doi.org/10.1016/0893-133x(94)00129-n"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2125.1998.00684.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021985463"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2125.1998.00684.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021985463"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/s0893-133x(96)00218-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026765776", 
          "https://doi.org/10.1016/s0893-133x(96)00218-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02245617", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029859444", 
          "https://doi.org/10.1007/bf02245617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02245617", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029859444", 
          "https://doi.org/10.1007/bf02245617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/0893-133x(95)00069-p", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031151871", 
          "https://doi.org/10.1016/0893-133x(95)00069-p"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02245615", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036045642", 
          "https://doi.org/10.1007/bf02245615"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02245615", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036045642", 
          "https://doi.org/10.1007/bf02245615"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0447.1970.tb02066.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038841887"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02246146", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039770985", 
          "https://doi.org/10.1007/bf02246146"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02246146", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039770985", 
          "https://doi.org/10.1007/bf02246146"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.1988.tb03393.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043375746"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0920-9964(97)00036-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043802411"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-199309030-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045187528", 
          "https://doi.org/10.2165/00002018-199309030-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002280050527", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045912711", 
          "https://doi.org/10.1007/s002280050527"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/s0893-133x(97)00111-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050086142", 
          "https://doi.org/10.1016/s0893-133x(97)00111-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1991.8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052234105", 
          "https://doi.org/10.1038/clpt.1991.8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(93)90272-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052334702"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(93)90272-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052334702"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004714-199710000-00010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060188059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004714-199710000-00010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060188059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004714-199710000-00010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060188059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1176/ajp.152.10.1444", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063483437"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1176/ajp.154.4.457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063484990"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1176/ajp.154.9.1248", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063485212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1192/bjp.154.5.672", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064170005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4088/jcp.v58n1103", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072207107"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075863021", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082886679", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083037831", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083133428", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1999-09", 
    "datePublishedReg": "1999-09-01", 
    "description": "Multicentre trials in patients with schizophrenia confirm that olanzapine is a novel antipsychotic agent with broad efficacy, eliciting a response in both the positive and negative symptoms of schizophrenia. Compared with traditional antipsychotic agents, olanzapine causes a lower incidence of extrapyramidal symptoms and minimal perturbation of prolactin levels. Generally, olanzapine is well tolerated. The pharmacokinetics of olanzapine are linear and dose-proportional within the approved dosage range. Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours. The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h. Smokers and men have a higher clearance of olanzapine than women and nonsmokers. After administering [14C]olanzapine, approximately 60% of the radioactivity was excreted in urine and 30% in faeces. Olanzapine is predominantly bound to albumin (90%) and alpha 1-acid glycoprotein (77%). Olanzapine is metabolised to its 10- and 4'-N-glucuronides, 4'-N-desmethylolanzapine [cytochrome P450 (CYP) 1A2] and olanzapine N-oxide (flavin mono-oxygenase 3). Metabolism to 2-hydroxymethylolanzapine via CYP2D6 is a minor pathway. The 10-N-glucuronide is the most abundant metabolite, but formation of 4'-N-desmethylolanzapine is correlated with the clearance of olanzapine. Olanzapine does not inhibit CYP isozymes. No clinically significant metabolic interactions were found between olanzapine and diazepam, alcohol (ethanol), imipramine, R/S-warfarin, aminophylline, biperiden, lithium or fluoxetine. Fluvoxamine, an inhibitor of CYP1A2, increases plasma concentrations of olanzapine; inducers of CYP1A2, including tobacco smoke and carbamazepine, decrease olanzapine concentrations. Orthostatic changes were observed when olanzapine and diazepam or alcohol were coadministered. Pharmacodynamic interactions occurred between olanzapine and alcohol, and olanzapine and imipramine, implying that patients should avoid operating hazardous equipment or driving an automobile while experiencing the short term effects of the combinations. Individual factors with the largest impact on olanzapine pharmacokinetics are gender and smoking status. The plasma clearance of olanzapine generally varies over a 4-fold range, but the variability in the clearance and concentration of olanzapine does not appear to be associated with the severity or duration of adverse effects or the degree of efficacy. Thus, dosage adjustments appear unnecessary for these individual factors. However, dosage modification should be considered for patients characterised by a combination of factors associated with decreased oxidative metabolism, for example, debilitated or elderly women who are nonsmokers.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00003088-199937030-00001", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085321", 
        "issn": [
          "0312-5963", 
          "1179-1926"
        ], 
        "name": "Clinical Pharmacokinetics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "name": "Olanzapine", 
    "pagination": "177-193", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "a89a84468dd2d9be5b39f7940a570d43253fdc6e5a59cb6f4488658f851013b2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10511917"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7606849"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00003088-199937030-00001"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035394480"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00003088-199937030-00001", 
      "https://app.dimensions.ai/details/publication/pub.1035394480"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000500.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00003088-199937030-00001"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003088-199937030-00001'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003088-199937030-00001'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003088-199937030-00001'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003088-199937030-00001'


 

This table displays all metadata directly associated to this object as RDF triples.

246 TRIPLES      21 PREDICATES      72 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00003088-199937030-00001 schema:about N117cbeb62a054bdda82224a319083a4a
2 N28a755d02e3842b7955f00c5b09bb180
3 N821ef24426fe4635a67c6f21d0eaab60
4 N8547b28d7c3041698720b8568d75549f
5 Nad8fea86a39042288f30cf492e69ed14
6 Nb55d2d05b6384606a1daedf3d8a37344
7 Nc0c13f5c625a4596b00da103a1fa0dc6
8 Nd2af9bc5b86d4b8f8aee353469e2d7ab
9 Nd339c95dcbb54f18a82f5b726efe0d23
10 Nf633e0ac000c46ce91609f90fb9af125
11 Nfc5fdcfefa7a4205bd373a58ab4797b2
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author Nd5d93e3473614783bd9366a3967d9167
15 schema:citation sg:pub.10.1007/bf02245615
16 sg:pub.10.1007/bf02245617
17 sg:pub.10.1007/bf02246146
18 sg:pub.10.1007/bf02251294
19 sg:pub.10.1007/s002280050527
20 sg:pub.10.1016/0893-133x(94)00129-n
21 sg:pub.10.1016/0893-133x(95)00069-p
22 sg:pub.10.1016/s0893-133x(96)00218-7
23 sg:pub.10.1016/s0893-133x(97)00111-5
24 sg:pub.10.1038/clpt.1991.8
25 sg:pub.10.2165/00002018-199309030-00003
26 https://app.dimensions.ai/details/publication/pub.1075863021
27 https://app.dimensions.ai/details/publication/pub.1082886679
28 https://app.dimensions.ai/details/publication/pub.1083037831
29 https://app.dimensions.ai/details/publication/pub.1083133428
30 https://doi.org/10.1002/j.1552-4604.1997.tb04272.x
31 https://doi.org/10.1002/j.1875-9114.1998.tb03143.x
32 https://doi.org/10.1016/0006-2952(93)90272-x
33 https://doi.org/10.1016/s0920-9964(97)00036-4
34 https://doi.org/10.1046/j.1365-2125.1998.00684.x
35 https://doi.org/10.1097/00004714-199710000-00010
36 https://doi.org/10.1111/j.1365-2125.1982.tb02050.x
37 https://doi.org/10.1111/j.1365-2125.1988.tb03393.x
38 https://doi.org/10.1111/j.1365-2125.1995.tb04422.x
39 https://doi.org/10.1111/j.1365-2125.1996.tb00180.x
40 https://doi.org/10.1111/j.1600-0447.1970.tb02066.x
41 https://doi.org/10.1176/ajp.152.10.1444
42 https://doi.org/10.1176/ajp.154.4.457
43 https://doi.org/10.1176/ajp.154.9.1248
44 https://doi.org/10.1192/bjp.154.5.672
45 https://doi.org/10.3109/00498258409151404
46 https://doi.org/10.4088/jcp.v58n1103
47 schema:datePublished 1999-09
48 schema:datePublishedReg 1999-09-01
49 schema:description Multicentre trials in patients with schizophrenia confirm that olanzapine is a novel antipsychotic agent with broad efficacy, eliciting a response in both the positive and negative symptoms of schizophrenia. Compared with traditional antipsychotic agents, olanzapine causes a lower incidence of extrapyramidal symptoms and minimal perturbation of prolactin levels. Generally, olanzapine is well tolerated. The pharmacokinetics of olanzapine are linear and dose-proportional within the approved dosage range. Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours. The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h. Smokers and men have a higher clearance of olanzapine than women and nonsmokers. After administering [14C]olanzapine, approximately 60% of the radioactivity was excreted in urine and 30% in faeces. Olanzapine is predominantly bound to albumin (90%) and alpha 1-acid glycoprotein (77%). Olanzapine is metabolised to its 10- and 4'-N-glucuronides, 4'-N-desmethylolanzapine [cytochrome P450 (CYP) 1A2] and olanzapine N-oxide (flavin mono-oxygenase 3). Metabolism to 2-hydroxymethylolanzapine via CYP2D6 is a minor pathway. The 10-N-glucuronide is the most abundant metabolite, but formation of 4'-N-desmethylolanzapine is correlated with the clearance of olanzapine. Olanzapine does not inhibit CYP isozymes. No clinically significant metabolic interactions were found between olanzapine and diazepam, alcohol (ethanol), imipramine, R/S-warfarin, aminophylline, biperiden, lithium or fluoxetine. Fluvoxamine, an inhibitor of CYP1A2, increases plasma concentrations of olanzapine; inducers of CYP1A2, including tobacco smoke and carbamazepine, decrease olanzapine concentrations. Orthostatic changes were observed when olanzapine and diazepam or alcohol were coadministered. Pharmacodynamic interactions occurred between olanzapine and alcohol, and olanzapine and imipramine, implying that patients should avoid operating hazardous equipment or driving an automobile while experiencing the short term effects of the combinations. Individual factors with the largest impact on olanzapine pharmacokinetics are gender and smoking status. The plasma clearance of olanzapine generally varies over a 4-fold range, but the variability in the clearance and concentration of olanzapine does not appear to be associated with the severity or duration of adverse effects or the degree of efficacy. Thus, dosage adjustments appear unnecessary for these individual factors. However, dosage modification should be considered for patients characterised by a combination of factors associated with decreased oxidative metabolism, for example, debilitated or elderly women who are nonsmokers.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree false
53 schema:isPartOf N555c5a2eadfe443d863e6cf005714c2b
54 N5ea1981e62064228bc3c51415abfabe5
55 sg:journal.1085321
56 schema:name Olanzapine
57 schema:pagination 177-193
58 schema:productId N406d5bbf690b4e9587fc5ff5be44fe4c
59 Nbe5b4162630142258b44cbca55d73a76
60 Nc55a7952ea354993b6489981e45b7552
61 Nc63b8797fa514aef892d55effa95f082
62 Neab5b8c12cb64084bcc2fcc967305878
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035394480
64 https://doi.org/10.2165/00003088-199937030-00001
65 schema:sdDatePublished 2019-04-10T18:18
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher Nff852c3f42ce4f1da0001192838b85d5
68 schema:url http://link.springer.com/10.2165/00003088-199937030-00001
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N117cbeb62a054bdda82224a319083a4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Antipsychotic Agents
74 rdf:type schema:DefinedTerm
75 N28a755d02e3842b7955f00c5b09bb180 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Multicenter Studies as Topic
77 rdf:type schema:DefinedTerm
78 N406d5bbf690b4e9587fc5ff5be44fe4c schema:name nlm_unique_id
79 schema:value 7606849
80 rdf:type schema:PropertyValue
81 N555c5a2eadfe443d863e6cf005714c2b schema:issueNumber 3
82 rdf:type schema:PublicationIssue
83 N57ea9ad928a140548fd0744c65d09d7a rdf:first sg:person.0635603377.04
84 rdf:rest N8916062f38fe4d4ab613424acb9ff5db
85 N5ea1981e62064228bc3c51415abfabe5 schema:volumeNumber 37
86 rdf:type schema:PublicationVolume
87 N821ef24426fe4635a67c6f21d0eaab60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Male
89 rdf:type schema:DefinedTerm
90 N8547b28d7c3041698720b8568d75549f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Drug Interactions
92 rdf:type schema:DefinedTerm
93 N8916062f38fe4d4ab613424acb9ff5db rdf:first sg:person.01362603742.12
94 rdf:rest Nb7d4179802044360ba960c422e80ffb2
95 N9b8acdaa74614749acf89cef66cd7696 schema:name Lilly Laboratory for Clinical Research, Indiana University Hospital and Outpatient Center, 550 North University Boulevard, 46202-5250, Indianapolis, Indiana, USA
96 Trilogy Consulting Corporation, Waukeganm, Illinois, USA
97 rdf:type schema:Organization
98 Nad8fea86a39042288f30cf492e69ed14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Female
100 rdf:type schema:DefinedTerm
101 Nb55d2d05b6384606a1daedf3d8a37344 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Continental Population Groups
103 rdf:type schema:DefinedTerm
104 Nb7d4179802044360ba960c422e80ffb2 rdf:first sg:person.01154671612.61
105 rdf:rest rdf:nil
106 Nbe5b4162630142258b44cbca55d73a76 schema:name readcube_id
107 schema:value a89a84468dd2d9be5b39f7940a570d43253fdc6e5a59cb6f4488658f851013b2
108 rdf:type schema:PropertyValue
109 Nc0c13f5c625a4596b00da103a1fa0dc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Benzodiazepines
111 rdf:type schema:DefinedTerm
112 Nc55a7952ea354993b6489981e45b7552 schema:name pubmed_id
113 schema:value 10511917
114 rdf:type schema:PropertyValue
115 Nc63b8797fa514aef892d55effa95f082 schema:name doi
116 schema:value 10.2165/00003088-199937030-00001
117 rdf:type schema:PropertyValue
118 Nd2af9bc5b86d4b8f8aee353469e2d7ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Pirenzepine
120 rdf:type schema:DefinedTerm
121 Nd339c95dcbb54f18a82f5b726efe0d23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Comorbidity
123 rdf:type schema:DefinedTerm
124 Nd5d93e3473614783bd9366a3967d9167 rdf:first sg:person.01324115133.87
125 rdf:rest N57ea9ad928a140548fd0744c65d09d7a
126 Neab5b8c12cb64084bcc2fcc967305878 schema:name dimensions_id
127 schema:value pub.1035394480
128 rdf:type schema:PropertyValue
129 Nf633e0ac000c46ce91609f90fb9af125 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Humans
131 rdf:type schema:DefinedTerm
132 Nfc5fdcfefa7a4205bd373a58ab4797b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Time Factors
134 rdf:type schema:DefinedTerm
135 Nff852c3f42ce4f1da0001192838b85d5 schema:name Springer Nature - SN SciGraph project
136 rdf:type schema:Organization
137 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
138 schema:name Medical and Health Sciences
139 rdf:type schema:DefinedTerm
140 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
141 schema:name Clinical Sciences
142 rdf:type schema:DefinedTerm
143 sg:journal.1085321 schema:issn 0312-5963
144 1179-1926
145 schema:name Clinical Pharmacokinetics
146 rdf:type schema:Periodical
147 sg:person.01154671612.61 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
148 schema:familyName Beasley
149 schema:givenName Charles M.
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154671612.61
151 rdf:type schema:Person
152 sg:person.01324115133.87 schema:affiliation https://www.grid.ac/institutes/grid.257413.6
153 schema:familyName Callaghan
154 schema:givenName John T.
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324115133.87
156 rdf:type schema:Person
157 sg:person.01362603742.12 schema:affiliation N9b8acdaa74614749acf89cef66cd7696
158 schema:familyName Ptak
159 schema:givenName Louis R.
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362603742.12
161 rdf:type schema:Person
162 sg:person.0635603377.04 schema:affiliation https://www.grid.ac/institutes/grid.257413.6
163 schema:familyName Bergstrom
164 schema:givenName Richard F.
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635603377.04
166 rdf:type schema:Person
167 sg:pub.10.1007/bf02245615 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036045642
168 https://doi.org/10.1007/bf02245615
169 rdf:type schema:CreativeWork
170 sg:pub.10.1007/bf02245617 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029859444
171 https://doi.org/10.1007/bf02245617
172 rdf:type schema:CreativeWork
173 sg:pub.10.1007/bf02246146 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039770985
174 https://doi.org/10.1007/bf02246146
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/bf02251294 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003233659
177 https://doi.org/10.1007/bf02251294
178 rdf:type schema:CreativeWork
179 sg:pub.10.1007/s002280050527 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045912711
180 https://doi.org/10.1007/s002280050527
181 rdf:type schema:CreativeWork
182 sg:pub.10.1016/0893-133x(94)00129-n schema:sameAs https://app.dimensions.ai/details/publication/pub.1020831678
183 https://doi.org/10.1016/0893-133x(94)00129-n
184 rdf:type schema:CreativeWork
185 sg:pub.10.1016/0893-133x(95)00069-p schema:sameAs https://app.dimensions.ai/details/publication/pub.1031151871
186 https://doi.org/10.1016/0893-133x(95)00069-p
187 rdf:type schema:CreativeWork
188 sg:pub.10.1016/s0893-133x(96)00218-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026765776
189 https://doi.org/10.1016/s0893-133x(96)00218-7
190 rdf:type schema:CreativeWork
191 sg:pub.10.1016/s0893-133x(97)00111-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050086142
192 https://doi.org/10.1016/s0893-133x(97)00111-5
193 rdf:type schema:CreativeWork
194 sg:pub.10.1038/clpt.1991.8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052234105
195 https://doi.org/10.1038/clpt.1991.8
196 rdf:type schema:CreativeWork
197 sg:pub.10.2165/00002018-199309030-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045187528
198 https://doi.org/10.2165/00002018-199309030-00003
199 rdf:type schema:CreativeWork
200 https://app.dimensions.ai/details/publication/pub.1075863021 schema:CreativeWork
201 https://app.dimensions.ai/details/publication/pub.1082886679 schema:CreativeWork
202 https://app.dimensions.ai/details/publication/pub.1083037831 schema:CreativeWork
203 https://app.dimensions.ai/details/publication/pub.1083133428 schema:CreativeWork
204 https://doi.org/10.1002/j.1552-4604.1997.tb04272.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1018789894
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1002/j.1875-9114.1998.tb03143.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1011721679
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/0006-2952(93)90272-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052334702
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1016/s0920-9964(97)00036-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043802411
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1046/j.1365-2125.1998.00684.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1021985463
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1097/00004714-199710000-00010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060188059
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1111/j.1365-2125.1982.tb02050.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1016181259
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1111/j.1365-2125.1988.tb03393.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043375746
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1111/j.1365-2125.1995.tb04422.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1014592236
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1111/j.1365-2125.1996.tb00180.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1018563641
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1111/j.1600-0447.1970.tb02066.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1038841887
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1176/ajp.152.10.1444 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063483437
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1176/ajp.154.4.457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063484990
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1176/ajp.154.9.1248 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063485212
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1192/bjp.154.5.672 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064170005
233 rdf:type schema:CreativeWork
234 https://doi.org/10.3109/00498258409151404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010674459
235 rdf:type schema:CreativeWork
236 https://doi.org/10.4088/jcp.v58n1103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072207107
237 rdf:type schema:CreativeWork
238 https://www.grid.ac/institutes/grid.257413.6 schema:alternateName Indiana University – Purdue University Indianapolis
239 schema:name Department of Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA
240 Departments of Medicine and Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA
241 Lilly Laboratory for Clinical Research, Indiana University Hospital and Outpatient Center, 550 North University Boulevard, 46202-5250, Indianapolis, Indiana, USA
242 rdf:type schema:Organization
243 https://www.grid.ac/institutes/grid.417540.3 schema:alternateName Eli Lilly (United States)
244 schema:name Eli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA
245 Lilly Laboratory for Clinical Research, Indiana University Hospital and Outpatient Center, 550 North University Boulevard, 46202-5250, Indianapolis, Indiana, USA
246 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...